Quick Answer
Evommune, Inc. reported Revenue (ASC 606) of $13.00 million for fiscal year 2025.
Evommune, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $13.00M | +85.7% |
| 2024 | $7.00M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $10.00M | — | — |
- Evommune, Inc. showed an increase of +85.7% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2024–2025 period, Evommune, Inc.’s revenue (asc 606) has grown by 85.7% (from $7.00 million to $13.00 million).
- The most recent figure is from Evommune, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: